BioSpace News Archive

With its FDA approval last week and first-to-market advantage, Madrigal Pharmaceuticals’ Rezdiffra will set the standard for other metabolic dysfunction-associated steatohepatitis candidates in development.

Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.

AstraZeneca reported Monday that adding Lynparza to Imfinzi improved outcomes in mismatch repair proficient endometrial cancer, more than doubling the median duration of response in patients.

New late-stage trial results for GSK’s Jemperli show improved overall and progression-free survival in a broader range of endometrial cancer patients, which could lead to a potential label expansion.

Contineum Therapeutics joined the 2024 initial public offering class on Friday with an SEC filing. The biotech will use the IPO proceeds to complete a Phase II trial for its most mature candidate targeting multiple sclerosis.

With Boehringer Ingelheim’s announcement earlier this month that it was capping U.S. inhaler costs at $35 per month, AstraZeneca on Monday followed suit.

BioSpace’s 2024 Salary Report explores the average salaries and salary trends of life sciences professionals.

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Association (NHIA) 2024 Conference.

Nortech Systems Incorporated (Nasdaq: NSYS) will hold a live conference call and webcast at 4:00 p.m. Central Time on Wednesday, March 20, 2024, to discuss the company’s fourth quarter financial results.

Madrigal Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.